Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam
- 1 August 2019
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 57 (8)
Abstract
Third-generation cephalosporin resistance among Enterobacteriaceae , mediated by the spread of extended-spectrum β-lactamases (ESBLs), is a very serious medical concern with limited therapeutic options. Enmetazobactam (formerly AAI101) is a novel penicillanic sulfone β-lactamase inhibitor active against a wide range of ESBLs. The combination of enmetazobactam and cefepime has entered phase 3 development in patients with complicated urinary tract infections.Keywords
This publication has 26 references indexed in Scilit:
- In Vivo Activities of Simulated Human Doses of Cefepime and Cefepime-AAI101 against Multidrug-Resistant Gram-Negative EnterobacteriaceaeAntimicrobial Agents and Chemotherapy, 2015
- Relationship between Antimicrobial Consumption and the Incidence of Antimicrobial Resistance in Escherichia coli and Klebsiella pneumoniae IsolatesJournal of Clinical and Diagnostic Research, 2015
- Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpCJournal of Antimicrobial Chemotherapy, 2015
- Determining a clinical framework for use of cefepime and -lactam/ -lactamase inhibitors in the treatment of infections caused by extended-spectrum- -lactamase-producing EnterobacteriaceaeJournal of Antimicrobial Chemotherapy, 2013
- Cefepime: a reappraisal in an era of increasing antimicrobial resistanceExpert Review of Anti-infective Therapy, 2008
- Statistical Methods for Establishing Quality Control Ranges for Antibacterial Agents in Clinical and Laboratory Standards Institute Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2007
- AmpC Disk Test for Detection of Plasmid-Mediated AmpC β-Lactamases in Enterobacteriaceae Lacking Chromosomal AmpC β-LactamasesJournal of Clinical Microbiology, 2005
- Increase in ampC promoter strength due to mutations and deletion of the attenuator in a clinical isolate of cefoxitin-resistant Escherichia coli as determined by RT–PCRJournal of Antimicrobial Chemotherapy, 2005
- Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance ThreatClinical Microbiology Reviews, 2001
- Characterization of the Extended-Spectrum β-Lactamase Reference Strain, Klebsiella pneumoniae K6 (ATCC 700603), Which Produces the Novel Enzyme SHV-18Antimicrobial Agents and Chemotherapy, 2000